Download PDF
Int J Sports Med 2016; 37(13): 1066-1072
DOI: 10.1055/s-0042-110205
Clinical Sciences
© Georg Thieme Verlag KG Stuttgart · New York

Physical Exercise in Patients with Fabry Disease – a Pilot Study

B. Schmitz
1   Institute of Sports Medicine, University Hospital Muenster, Muenster, Germany
,
L. Thorwesten
1   Institute of Sports Medicine, University Hospital Muenster, Muenster, Germany
,
M. Lenders
2   Department of Nephrology, Hypertension and Rheumatology, Internal Medicine D, University Hospital Muenster, Muenster, Germany
,
T. Duning
3   Department of Neurology, University Hospital Muenster, Muenster, Germany
,
J. Stypmann
4   Department of Cardiovascular Medicine, Division of Cardiology, University Hospital Muenster, Muenster, Germany
,
E. Brand
2   Department of Nephrology, Hypertension and Rheumatology, Internal Medicine D, University Hospital Muenster, Muenster, Germany
,
S.-M. Brand
1   Institute of Sports Medicine, University Hospital Muenster, Muenster, Germany
› Author Affiliations
Further Information

Publication History



accepted after revision 16 February 2016

Publication Date:
27 September 2016 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to assess the extent of exercise intolerance in Fabry disease (FD) patients and to report individual effects of physical exercise. Exercise capacity and strength of 14 patients (mean age 46 years, 6 females) were determined using cycle ergometry and isokinetic measurements. Patients performed a strength/circuit exercise training protocol for 12 months. The mean relative maximum performance of the group was low at baseline and increased by 12.1% (baseline: 1.9 [0.9−3.4] W·kg−1 vs. re-test: 2.1 [1.1–3.8] W·kg−1; p=0.035) during the study. Patients’ mean baseline maximum performance blood lactate of 5.4 [1.3–9.9] mmol·L−1 increased to a mean of 7.2 (2.4–10.2) mmol·L−1 (p=0.038). Mean strength of the lower limbs (left/right extensors and flexors, total work of 5 sets) changed from 2269 (1017–2913) kg·m2·s - 2 to 2325 (1359–3107) kg·m2·s-2 (not significant). Patients reported increased well-being, daily activity and reduced fatigue during the study. Our results indicate that exercise intolerance in FD patients often results from physical inactivity. FD patients may perform exercise training to improve exercise capacity and muscle strength. Future studies will address the clinical benefits of exercise in FD.

Key words

rare disease - lysosome - α-Galactosidase A - globotriaosylceramide

Supplementary Material

 

  • References

  • 1 Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis 2015; 10: 77
    CrossrefPubMedGoogle Scholar
  • 2 Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006; 29: 572-579
    CrossrefPubMedGoogle Scholar
  • 3 Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respiration 2005; 72: 504-511
    CrossrefPubMedGoogle Scholar
  • 4 Bouwman MG, Maurice-Stam H, Linthorst GE, Hollak CE, Wijburg FA. Grootenhuis MA. Mol Genet Metab 2011; 104: 308-313
    CrossrefPubMedGoogle Scholar
  • 5 Calcagnino M, O'Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K, Mehta A, Hughes D, Murphy E, Lachmann R, Elliott PM. Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. J Am Coll Cardiol 2011; 58: 88-89
    CrossrefPubMedGoogle Scholar
  • 6 Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347-352
    PubMedGoogle Scholar
  • 7 Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. J Lab Clin Med 1973; 81: 157-171
    PubMedGoogle Scholar
  • 8 Dolny DG, Collins MG, Wilson T, Germann ML, Davis HP. Validity of lower extremity strength and power utilizing a new closed chain dynamometer. Med Sci Sports Exerc 2001; 33: 171-175
    PubMedGoogle Scholar
  • 9 Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, Leon AS, Piña IL, Rodney R, Simons-Morton DA, Williams MA, Bazzarre T. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 1694-1740
    CrossrefPubMedGoogle Scholar
  • 10 Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP. American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43: 1334-1359
    CrossrefPubMedGoogle Scholar
  • 11 Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30
    CrossrefPubMedGoogle Scholar
  • 12 Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015; 52: 353-358
    CrossrefPubMedGoogle Scholar
  • 13 Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010; 99: 283-290
    CrossrefPubMedGoogle Scholar
  • 14 Harriss DJ, Atkinson G. Ethical standards in sports and exercise science research: 2016 update. Int J Sports Med 2015; 36: 1121-1124
    Google Scholar
  • 15 Hughes DA, Mehta AB. Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta Paediatr Suppl 2005; 94: 28-33
    CrossrefPubMedGoogle Scholar
  • 16 Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology 2015; 84: 1009-1016
    CrossrefPubMedGoogle Scholar
  • 17 Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E, Becker G. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 2008; 38: 407-414
    CrossrefPubMedGoogle Scholar
  • 18 Löllgen H, Erdmann E, Gitt AK. Ergometrie. 3rd ed. Springer; 2009: 70-71
    Google Scholar
  • 19 Lorenzen JM, Dietrich B, Fiedler J, Jazbutyte V, Fleissner F, Karpinski N, Weidemann F, Wanner C, Asan E, Caprio M, Ertl G, Bauersachs J, Thum T. Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. Basic Res Cardiol 2013; 108: 311
    CrossrefPubMedGoogle Scholar
  • 20 MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-760
    CrossrefPubMedGoogle Scholar
  • 21 Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin Chim Acta 1981; 112: 247-251
    CrossrefPubMedGoogle Scholar
  • 22 Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT. Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 2009; 374: 1986-1996
    CrossrefPubMedGoogle Scholar
  • 23 Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257: 258-263
    CrossrefPubMedGoogle Scholar
  • 24 Namdar M, Gebhard C, Studiger R, Shi Y, Mocharla P, Schmied C, Brugada P, Lüscher TF, Camici GG. Globotriaosylsphingosine accumulation and not alpha-galactosidase A deficiency causes endothelial dysfunction in Fabry disease. PLoSOne 2012; 7: e3637
    PubMedGoogle Scholar
  • 25 O'Donovan G, Blazevich AJ, Boreham C, Cooper AR, Crank H, Ekelund U, Fox KR, Gately P, Giles-Corti B, Gill JM, Hamer M, McDermott I, Murphy M, Mutrie N, Reilly JJ, Saxton JM, Stamatakis E. The ABC of Physical Activity for Health: a consensus statement from the British Association of Sport and Exercise Sciences. J Sports Sci 2010; 28: 573-591
    CrossrefPubMedGoogle Scholar
  • 26 Rolfs A, Martus P, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, Böttcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B. sifap1 Investigators. Protocol and methodology of the Stroke in Young Fabry Patients (sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18–55 years. Cerebrovasc Dis 2011; 31: 253-262
    CrossrefPubMedGoogle Scholar
  • 27 Schiffman R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study onf individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis 2015; 38: 1129-1136
    CrossrefPubMedGoogle Scholar
  • 28 Spinelli L, Nicolai E, Acampa W, Imbriaco M, Pisani A, Rao MA, Scopacasa F, Cianciaruso B, De Luca N, Cuocolo A. Cardiac performance during exercise in patients with Fabry's disease. Eur J Clin Invest 2008; 38: 910-917
    CrossrefPubMedGoogle Scholar
  • 29 van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, Bussmann JB, van Doorn PA, van der Ploeg AT. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis 2015; 10: 87
    CrossrefPubMedGoogle Scholar
  • 30 Zarate YA, Hopkin RJ. Fabry’s disease. Lancet 2008; 372: 1427-1435
    CrossrefPubMedGoogle Scholar